Gore* None Mark A. Creager Brigham and Women s Hospital Medtronic ; NIH None None None None AstraZeneca ; Baxter Healthcare*; Merck (via TIMI Group)*; Novartis*; Takeda* None Robert H. Eckel University of Colorado at Denver None None None None None Amarin*; Amylin*; Genetech*; Janssen, Johnson & Johnson*; Lilly*; Novo Nordisk*; Regulus*; Sanofi-Aventis* None Mitchell S.V. Elkind Columbia University BMS/Sanofi ; diaDexus, Inc NIH None None Merck Organon (Nuvaring and stroke) ; Novartis (aliskiren and stroke)* None BMS-Pfizer Pharmaceutical Partnership*; Janssen*; Daiichi Sankyo*; Biogen IDEC* None Myriam Fornage University of Texas Health Science Center at Houston None None None None None None None Larry B. Goldstein Duke University None None Pfizer* None None Daiichi Sankyo* None Steven M. Greenberg Massachusetts General Hospital NIH/NINDS None None None None None None Susanna E. Horvath Columbia University None None None None None None None Costantino Iadecola Weill Cornell Medical College None None None None None None None Edward C. Jauch Medical University of South Carolina NIH/NINDS None None None None None None Wesley S. Moore University of California at Los Angeles None None None None None None None John A. Wilson Wake Forest School of Medicine None None None None None None None This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be significant if (a) the person receives $10000 or more during any 12-month period, or 5% or more of the person s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10000 or more of the fair market value of the entity. 